Released Aug 10, 2023, before the open
10-Q filed Aug 10, 2023, 41 days after period end · 0001785530-23-000025
Q2 2023 · 10-Q
Revenue—
Net Income-$5.10M-$5.10M N/M vs Q2 2022N/M vs Q1 2023
EPS Diluted-$0.14-$0.14 N/M vs Q2 2022N/M vs Q1 2023
Operating Income-$6,067,000N/M
Operating Cash Flowderived-$10,921,000N/M
Free Cash Flowderived-$11,103,000N/M
What the release said
The release
Same quarter
| Metric | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 |
|---|---|---|---|---|
| Net Income | -$5.10M | -$14.59M | -$10.92M | $2.26M |
| EPS Diluted | -$0.14 | -$0.53 | -$3.82 | $0.22 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Werewolf Therapeutics, Inc. · CIK 1785530 · Engraved from SEC EDGAR